Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonrotoclax + zanubrutinib versus venetoclax + acalabrutinib in previously untreated chronic lymphocytic leukemia
2025-524366-21-00Phase 3Authorised
- Sponsor
- BeOne Medicines
- Start
- Apr 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, open-label trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Sonrotoclax + zanubrutinib with Venetoclax + acalabrutinib (2 arms). Primary endpoint: Progression-free survival. Planned start Apr 2026; status: authorised.
02
Drugs
sonrotoclaxzanubrutinibvenetoclaxacalabrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2025-524366-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524366-21-00.